Skip to main
PAVM
PAVM logo

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. is positioned for considerable growth due to its diverse pipeline of medical technologies, which includes established products like EsoGuard and the Veris Cancer Care Platform. The company’s current valuation is deemed attractive, reflecting a balance between inherent risks and substantial upside potential, with expectations for significant revenue growth as its products advance through commercialization, particularly in 2025 and 2026. This favorable outlook is underscored by a projected increase in the company's net present value (NPV) assessment, indicating confidence in its long-term financial performance.

Bears say

PAVmed Inc reported a pro forma net loss of $0.8 million for the quarter, leading to an EPS of $(0.05), which was significantly better than the consensus estimate range of $(0.13) to $(0.25). However, the company experienced a decline in its EsoGuard test processing, registering only 2,756 tests in Q2 compared to prior quarters, indicating potential challenges in demand or market acceptance. Furthermore, the outlook is marred by multiple risk factors including liquidity concerns, regulatory hurdles, competition, and shifting investor sentiment in the biotech and medtech sectors, which could impede future growth and commercialization efforts.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.